Market Overview - On November 12, the total trading volume of stocks on the Beijing Stock Exchange reached 913 million shares, with a total transaction value of 19.915 billion yuan, a decrease of 5.84 billion yuan compared to the previous trading day [1] - Among the tradable stocks, 128 stocks closed higher, accounting for 45.55% of the total, with notable gainers including Sanyuan Gene, Danna Biological, and Luqiao Information, which rose by 12.45%, 9.99%, and 7.21% respectively [1] - Conversely, 147 stocks closed lower, with the largest declines seen in Huifeng Diamond, Gaisi Food, and Litong Technology, which fell by 9.06%, 7.31%, and 6.88% respectively [1] Trading Activity - A total of 60 stocks had transaction values exceeding 100 million yuan, with the highest transaction values recorded for Andar Technology, Zhu Laoliu, and Better Ray, at 566.33 million yuan, 535.27 million yuan, and 490.44 million yuan respectively [1] - In terms of trading activity, 24 stocks had a turnover rate exceeding 10%, with 5 stocks exceeding 20%. Additionally, 46 stocks had turnover rates between 5% and 10%, while 189 stocks had turnover rates between 1% and 5% [1] - The stocks with the highest turnover rates included Danna Biological, Zhu Laoliu, and Gaisi Food, with turnover rates of 39.96%, 35.73%, and 30.83% respectively [1] Notable Stocks - The closing prices and performance of notable stocks include: - Andar Technology: 8.19 yuan, down 1.92%, turnover rate 15.32%, transaction value 566.34 million yuan [1] - Zhu Laoliu: 25.12 yuan, down 3.38%, turnover rate 35.73%, transaction value 535.27 million yuan [1] - Better Ray: 34.55 yuan, down 2.48%, turnover rate 1.29%, transaction value 490.44 million yuan [1] - Sanyuan Gene: 33.15 yuan, up 12.45%, turnover rate 7.52%, transaction value 27.64 million yuan [1] - Danna Biological: 85.45 yuan, up 9.99%, turnover rate 39.96%, transaction value 239.83 million yuan [1]

Core Insights - The first domestically developed gene engineering Class I new drug, human interferon α1b (Yunde Su), is showing unique potential in cancer treatment, emphasizing "Chinese wisdom" in the field [1] Group 1: Event Overview - The "2025 Annual Academic Salon of Academicians and Experts" was held by Sanyuan Gene Pharmaceutical Co., Ltd. in Beijing, focusing on the innovative application of human interferon α1b in treating malignant tumors [1] - The event was guided and funded by the Beijing Association for Science and Technology, gathering top oncology experts from various prestigious institutions [3] Group 2: Strategic Value of Old Drugs - Academician Hou Yunde, known as the "father of Chinese interferon," highlighted that while interferon is an old drug, interferon α1b is a new drug with significant advantages in cancer treatment, including the ability to improve efficacy through higher dosages and expand clinical indications [4] - Continuous innovation by clinical experts and Sanyuan Gene in new formulations and administration methods for interferon has established a high-quality brand in China [4] Group 3: Clinical Data and Research Findings - Experts shared significant research results on the efficacy of interferon α1b in treating melanoma, particularly in the context of its unique characteristics compared to Western treatments [5] - A new high-level randomized controlled clinical research plan was announced, indicating that combination therapy based on human interferon α1b is effective and safe for various types of melanoma [5] Group 4: Expert Consensus and Guidelines - The latest expert consensus on the treatment of melanoma with interferon α1b was presented, confirming its safety and efficacy through numerous cases [6] - The treatment protocol for melanoma using interferon α1b has been officially included in the 2025 edition of the Chinese Anti-Cancer Association (CACA) melanoma guidelines, marking a significant recognition of domestically developed innovative drugs [6] Group 5: Future Directions - A high-level dialogue session was held to explore future research directions and application potential of interferon α1b, showcasing the event as a platform for academic achievements and promoting the value of original research drugs in cancer treatment [7]

Summary of Key Points Core Viewpoint - On October 31, the Beijing Stock Exchange (BSE) saw a total trading volume of 1.299 billion shares and a trading value of 32.323 billion yuan, representing a decrease of 10.622 billion yuan compared to the previous trading day. A total of 219 stocks closed higher, indicating a positive market sentiment despite the drop in trading volume [1]. Trading Performance - The trading volume for the BSE was 1.299 billion shares, with a trading value of 32.323 billion yuan, down from the previous day by 10.622 billion yuan [1]. - Among the traded stocks, 219 stocks rose, accounting for 78.49% of the total, with notable gainers including Lijia Technology (up 13.91%), Deyuan Pharmaceutical (up 13.09%), and Sanyuan Gene (up 13.07%) [1]. - Conversely, 55 stocks declined, with Huifeng Diamond, Jiuling Technology, and Mezhigao experiencing the largest drops of 6.34%, 4.96%, and 4.57% respectively [1]. Active Stocks - A total of 93 stocks had a trading value exceeding 100 million yuan, with the highest trading values recorded for Beiterui (1.359 billion yuan), Fujida (999.5 million yuan), and Guozi Software (709.8 million yuan) [1]. - The trading activity was characterized by 46 stocks having a turnover rate exceeding 10%, with 8 stocks exceeding 20%. The highest turnover rates were seen in Digital Human (32.55%), Jinhua New Materials (28.91%), and Taikai Ying (27.85%) [1]. Notable Stock Details - Key stocks and their performance included: - Beiterui: Closing price 36.45 yuan, up 4.71%, turnover rate 3.29%, trading value 1.359 billion yuan [1]. - Guozi Software: Closing price 44.70 yuan, up 11.75%, turnover rate 26.35%, trading value 709.8 million yuan [1]. - Deyuan Pharmaceutical: Closing price 41.30 yuan, up 13.09%, turnover rate 12.64%, trading value 523.0 million yuan [1].

Core Insights - San Yuan Gene reported a revenue of 163 million yuan for the first three quarters of 2025, with a net cash flow from operating activities of 22.52 million yuan, indicating a strong performance in the biopharmaceutical sector [1][2] - The company is actively promoting innovation in research and development and intelligent manufacturing, aligning with national policies aimed at advancing the biopharmaceutical industry [1][2] Industry Developments - The biopharmaceutical industry is undergoing significant transformation, supported by national policies that encourage digital transformation and integration with new information technologies [1] - The Ministry of Industry and Information Technology and other departments have set a goal for comprehensive digital transformation of pharmaceutical enterprises by 2030, providing a clear direction for industry development [1] Company Initiatives - San Yuan Gene is focusing on building a dynamic digital twin platform for biopharmaceuticals, which integrates multi-source data and algorithmic models to enhance manufacturing flexibility and operational efficiency [1][2] - The company has established a smart ecosystem that covers the entire supply chain, enhancing product quality, production efficiency, and market competitiveness in the context of centralized procurement policies [2] Achievements and Future Plans - The company has made significant progress in its smart factory construction project, achieving key objectives in data integration and innovation-driven manufacturing [2] - San Yuan Gene has received accolades such as "2025 Advanced Intelligent Factory in Beijing" and "2025 Green Lighthouse Factory in Shanghai," reflecting its commitment to intelligent manufacturing [2] - Future plans include further integrating digital twin technology with AI models to create an open collaborative platform for the biopharmaceutical industry, providing innovative solutions for digital transformation [2]

| 专门委员会名称 | 委员 | 主任委员（召集人） | | --- | --- | --- | | 审计委员会 | 钱爱民、邵荣光、杨大军 | 钱爱民 | | 薪酬与考核委员会 | 邵荣光、钱爱民、杨大军 | 邵荣光 | | 战略与可持续发展 | 程永庆、范保群、胡左浩 | 程永庆 | | 委员会 | | | 二、调整后： 证券代码：920344 证券简称：三元基因 公告编号：2025-111 | 专门委员会名称 | 委员 | 主任委员（召集人） | | --- | --- | --- | | 审计委员会 | 钱爱民、邵荣光、许大海 | 钱爱民 | | 薪酬与考核委员会 | 邵荣光、胡左浩、杨大军 | 邵荣光 | | 战略与可持续发展 | 程永庆、范保群、胡左浩 | 程永庆 | | 委员会 | | | 北京三元基因药业股份有限公司 调整后的董事会专门委员会委员的任期自本次董事会审议通过 之日起至第四届董事会届满之日止，与公司第四届董事会任期一致。 关于调整公司第四届董事会专门委员会委员的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准 ...

证券代码：920344 证券简称：三元基因 公告编号：2025-110 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 10 月 27 日 北京三元基因药业股份有限公司 第四届董事会第九次会议决议公告 2.会议召开地点：公司会议室 3.会议召开方式：现场+通讯方式 4.发出董事会会议通知的时间和方式：2025 年 10 月 16 日以通讯 方式发出。 5.会议主持人：会议由程永庆董事长主持。 6.会议列席人员：董事会秘书以及公司其他高级管理人员列席了 会议。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 7.召开情况合法合规的说明： 会议的召开符合《公司法》和《公司章程》等有关规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事程十庆、胡左浩因工作原因以通讯方式参与表决。 二、议案审议情况 （一）审议通过《2025 年第三季度报告》 1.议案内容： 具体内容详见公司于 2025 年 10 月 29 日在北京证券交易所官网 （www.bse. ...

Market Overview - The biopharmaceutical sector experienced a decline of 0.57% on October 22, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wendi Pharmaceutical (688488) with a closing price of 14.77, up 4.01% [1] - Dongbao Bio (300239) at 5.78, up 2.66% [1] - Jinke (688670) at 17.03, up 2.59% [1] - Major decliners included: - Aopumai (688293) at 55.19, down 4.40% [2] - Wofu Bio (300357) at 31.63, down 3.18% [2] - Sanofi (688336) at 59.60, down 2.39% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 192 million yuan from institutional investors, while retail investors contributed a net inflow of 53.82 million yuan [2] - Specific stock capital flows included: - Te Bao Bio (688278) with a net inflow of 19.00 million yuan from institutional investors [3] - Hualan Bio (002007) with a net inflow of 12.05 million yuan from institutional investors [3] - Aopumai (688293) with a net outflow of 4.40% from institutional investors [3]

北京浩天律师事务所 HYLANDS LAW FIRM 中国北京市朝阳区东三环中路5号财富金融中心 3 层、11层、12层 12F Fortune Financial Center, No.5 Mid Rd, East 3rd Ring, Chaoyang District, Beijing 100020, China 电话 Tel: （86-10）65028888，传真 Fax: (86-10) 65028877 网址: http://www.hylandslaw.com 关于北京三元基因药业股份有限公司 2025年第三次临时股东会之法律意见书 致:北京三元基因药业股份有限公司 根据《中华人民共和国公司法》《中华人民共和国证券法》《北京证券交 易所股票上市规则》等现行有效的法律法规、规范性文件,以及北京三元基因 药业股份有限公司章程》（以下简称"公司章程"）的规定,北京浩天律师事 务所（以下简称"本所"）接受北京三元基因药业股份有限公司（以下简称"公 司"）委托,指派本所康乃馨律师、戚萌律师(以下简称"本所律师")出席公 司 2025年第三次临时股东会会议(以下简称"本次股东会"),对本次股东会的 相关事项依 ...

证券代码：920344 证券简称：三元基因 公告编号：2025-107 北京三元基因药业股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 10 月 17 日 2.会议召开地点：公司会议室 6.召开情况合法合规的说明： 3.会议召开方式：现场投票和网络投票相结合的方式 4.会议召集人：董事会 5.会议主持人：董事长程永庆 会议的召集、召开、议案审议程序符合《公司法》等有关法律、 法规和《公司章程》的规定。 出席和授权出席本次股东会的股东共 11 人，持有表决权的股份 总数 61,240,271 股，占公司有表决权股份总数的 50.2752%。 其中通过网络投票参与本次股东会的股东共 3 人，持有表决权的 股份总数 2,342,366 股，占公司有表决权股份总数的 1.9230%。 通过现场和网络参加本次股东会的中小股东（除公司董事、高级 管理人员及其关联方，以及单独或者合计持有公司 ...

Core Viewpoint - The A-share market shows a positive trend with the Shanghai Composite Index closing at 3897.56 points, above the six-month moving average, reflecting a slight increase of 0.21% [1] Group 1: Market Performance - The total trading volume of A-shares reached 1681.524 billion yuan today [1] - A total of 127 A-shares have surpassed the six-month moving average, indicating a bullish sentiment in the market [1] Group 2: Individual Stock Performance - Stocks with significant deviations from the six-month moving average include: - Ainanju (证券代: 920770) with a deviation rate of 9.77% and a daily increase of 12.36% [1] - Huifeng Diamond (证券代: 920725) with a deviation rate of 5.80% and a daily increase of 12.63% [1] - Kaitian Gas (证券代: 920010) with a deviation rate of 5.69% and a daily increase of 7.07% [1] - Other notable stocks with smaller deviations include Jiangzhong Pharmaceutical, Qingdao Port, and Ningbo Energy, which have just crossed the six-month moving average [1]